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In nonhigh risk patients with hypertrophic cardiomyopathy (HC), the presence of extensive
late gadolinium enhancement (LGEext) at cardiovascular magnetic resonance (CMR) imag-
ing has been proposed as a risk modifier in the decision process for implantable cardi-
overter defibrillator implantation. With a pretest risk of about 10%, a strategy that alters
the likelihood of LGEext could markedly affect efficacious CMR imaging. Our aim was to
study the potential of clinical variables and biomarkers to predict LGEext. In 98 HC patients
without any clear indication for implantable cardioverter defibrillator implantation, we
determined the discriminative values of a set of clinical variables and a panel of biomarkers
(hs-cTnT, NTproBNP, GDF-15, and Gal-3, CICP) for LGEext, that is, LGE 15% of the
left ventricular mass. LGEext was present in 10% (10/98) of patients. The clinical prediction
model contained a history of nonsustained ventricular tachycardia, maximal wall thickness
and reduced systolic function (c-statistic: 0.868, p <0.001). Of all biomarkers, only hs-cTnT
was associated with LGEext, in addition to the improved clinical model of diagnostic accu-
racy (p = 0.04). A biomarker-only strategy allowed the exclusion of LGEext in half of the
cohort, in case of a hs-cTnT concentration less than the optimal cutoff (Youden index; 8 ng/
L—sensitivity 100%, specificity 54%). In conclusion, in this nonhigh risk HC cohort, the
pretest likelihood of LGEext can be altered using clinical variables and the addition of hs-
cTnT. The promising findings with the use of hs-cTnT only call for new initiatives to study
its impact on efficacious CMR imaging in a larger HC population, either with or without
additional use of clinical variables. © 2018 The Authors. Published by Elsevier Inc. This
is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/) (Am J Cardiol 2018;122:483489)
Hypertrophic cardiomyopathy (HC) is a major cause of
sudden cardiac death (SCD) with an incidence of <1% per
year, which poses a major clinical challenge for its predic-
tion.1,2 Importantly, the highest absolute number of SCDs
still occur in the large group of nonhigh risk HC patients
without a clear indication for an implantable cardioverter
defibrillator.14 Recently, clinical experts have suggested
to incorporate extensive late gadolinium enhancement
(LGE) in clinical decision making for this category of HC
patients.5 As extensive LGE (15% of left ventricular
[LV] mass) is only seen in about 10%,6 a strategy based on
easily obtainable characteristics that would alter the pretest
likelihood, would be a more cost-effective approach than
routine LGE cardiovascular magnetic resonance (CMR)
imaging.7,8 In addition to various clinical variables (e.g.,
LV mass, wall thickness, and nonsustained ventricular
tachycardia [NSVT]911) biomarkers like cardiac troponin,
natriuretic peptides, and markers of collagen turnover have
repeatedly been associated with LGE in HC.1219 In the
previously mentioned clinical context, we aimed to identify
predictors of extensive LGE between routinely assessed
clinical variables and a broad panel of biomarkers in non-
high risk HC patients. In addition, we demonstrate the
predictive value of the addition of biomarkers in com-
parison to a prediction model with clinical variables
only.
Methods
For this analysis, we selected nonhigh risk patients from
a large cohort of HC patients who participated in a Dutch
multicenter study on CMR imaging and biomarkers.20 In
short, adult HC patients from different hospitals were
enrolled at 2 outpatient clinics (Radboud University Medi-
cal Center, Nijmegen and Albert Schweitzer Hospital, Dor-
drecht, The Netherlands) from 2008 to 2014. Patients had
to fulfill the diagnostic criteria for HC according to the pre-
vailing guidelines at the time of inclusion and should not
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have a history of coronary artery disease or septal reduction
therapy. For this analysis, data on the extent of LGE had to
be available. Furthermore, we selected HC patients who are
considered not to be at high SCD risk based on the Ameri-
can Heart Association (AHA)/American College of Cardi-
ology (ACC) guidelines (i.e., low to intermediate risk HC
patients). Accordingly, we excluded patients with a family
history of SCD, extreme hypertrophy (30 mm) or a recent
unexplained syncope (i.e., patients in whom ICD implanta-
tion is considered reasonable according to the latest AHA/
ACC guidelines).2 The study complies with the Declaration
of Helsinki and the protocol was approved by the local ethi-
cal committees and conducted accordingly. All participants
provided written informed consent.
CMR imaging was performed on 1.5 T CMR systems
(Philips Achieva [Philips Healthcare, Best, The Nether-
lands] or Siemens Avanto [Siemens Health Care, Erlangen,
Germany]) according to local imaging protocols, as previ-
ously described in more detail.20 T1-weighted inversion-
recovery imaging was performed to assess LGE 10 minutes
after the administration of 0.2 mmol/kg contrast medium
(Dotarem; Guerbet, Gorinchem, The Netherlands).
Images were analyzed with commercially available soft-
ware (QMass 7.5, Medis, Leiden, The Netherlands) by three
observers (FG, JB, and HD) unaware of the subjects’ clini-
cal information. The extent of LGE was scored visually
according to a semi-quantitative score, previously validated
in HC.21 The definition of extensive LGE was met in case
the LGE extent comprised 15% of the LV mass.
Blood samples were obtained by trained personnel and
processed within 60 minutes after phlebotomy, and stored
at ¡80˚C until further analysis. Serum samples were
used for the determination of the biomarkers (1) cardiac tro-
ponin T using the highly sensitive assay (hs-cTnT), (2) N-
terminal-pro-B-type-natriuretic peptide (NTproBNP), (3)
Galectin-3 (Gal-3), (4) soluble tumorigenicity suppressor2
(sST2), (5) growth differentiation factor-15 (GDF-15),
and (6) C-terminal propeptide of type I collagen (CICP).
Variability and performance in healthy controls and
patients with heart failure have been published.22 We refer
to Appendix A for a detailed description of the assays.
Continuous variables are presented as means (§standard
deviations) or medians (interquartile ranges) and were com-
pared between patients with and without extensive LGE
using a Student’s t or MannWhitney U test, whichever is
appropriate. Dichotomous variables were compared using a
chi-square or Fisher’s exact test, whichever appropriate. A
p value of <0.05 was considered significant (two-sided).
Then, multivariable regression analysis was performed. A
stepwise forward approach was adopted to predict exten-
sive LGE based on the likelihood-ratio-test (P-in, 0.05; P-
out, 0.10). First, we constructed a model for prediction of
extensive LGE with the clinical variables that differed
between patients with and without extensive LGE (p
<0.10; model 1). Second, we constructed model 2 for pre-
diction of extensive LGE with the addition of the bio-
markers that differed between patients with and without
extensive LGE (p <0.10). To assess the calibration of the
models, we used the HosmerLemeshow goodness-of-fit
statistical method. Receiver operating characteristic (ROC)
analysis using c-statistics was performed to determine the
area under the curve of both models, and of each biomarker
variable included in model 2 separately. The cut-off value
for the continuous variables was determined using the You-
den index. Statistical analysis was performed with IBM
SPSS Statistics 22 (IBM Corp, Armonk, New York).
Results
For the present analysis, 98 nonhigh HC patients
selected from our total HC cohort of 141 HC patients were
studied (61% male, age 55 § 14 years) (Figure 1 and
Table 1).20 Most patients were a- or mildly symptomatic
with 96 (98%) in New York Heart Association class I to II.
The presence of LGE was demonstrated in 56 (57%)
patients. In these 56 patients, the extent of LGE comprised
8% (interquartile ranges 3 to 13%) of the LV mass. In
10 (10%) patients the extent of LGE was 15%.
Figure 1. Flow chart of our HC study population.
Our total HC population comprised 141 HC patients. Twenty-six HC patients were excluded because there was no data available on LGE extent. Seventeen
HC patients were excluded because they were considered to be at high SCD risk according to the ACC/AHA guidelines, in which an ICD implantation is con-
sidered reasonable.
ACC = American college of cardiology; AHA =American heart association; FH-SCD = family history of sudden cardiac death; HC = hypertrophic cardiomy-
opathy; ICD = implantable cardioverter defibrillator; LGE = late gadolinium enhancement; MRI = magnetic resonance imaging; SCD = sudden cardiac death.
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Patients with extensive LGE tended to be younger at the
time of diagnosis compared with patients without extensive
LGE (Table 1). Atrial fibrillation tended to be more often
present in patients with extensive LGE. A history of NSVTs
was more often present in these patients. With regard to
echocardiographic parameters, patients with extensive LGE
had a higher LV mass indexed to BSA and had a numeri-
cally higher maximal LV wall thickness. Lastly, 3 of 10
patients with extensive LGE had a reduced LV systolic func-
tion compared with 5 of 88 patients without extensive LGE.
The median hs-cTnT concentration was twice as high in
patients with extensive LGE (Table 2). No significant dif-
ferences were observed for NTproBNP or any of the other
biomarkers.
After multivariable regression analysis with the clinical
variables, the clinical prediction model consisted of a
Table 1
Baseline characteristics stratified according to extensive late gadolinium enhancement
Variable LGE extent p value
Total <15% 15%
(n = 98) (n = 88) (n = 10)
Age at participation (years) 55 § 14 55 § 15 57 § 12 0.74
Men 60 (61%) 53 (60%) 7 (70%) 0.74
Age at diagnosis (years)* 49 § 16 50 § 16 40 § 16 0.09
Pathogenic mutation present 46 (53%) 39 (50%) 7 (78%) 0.16
Atrial fibrillation* 18 (18%) 14 (16%) 4 (40%) 0.08
Hypertension 40 (41%) 35 (40%) 5 (50%) 0.74
Current smoker 15 (15%) 14 (16%) 1 (10%) 1.0
Dyslipidemiay 29 (30%) 24 (27%) 5 (50%) 0.16
Diabetes mellitus 5 (5%) 4 (5%) 1 (10%) 0.42
Creatinine (mmol/l) 84 § 16 84 § 16 89 § 20 0.37
Systolic blood pressure (mm Hg) 131 § 22 131 § 22 133 § 20 0.76
Heart rate (beats/minute) 73 § 12 73 § 12 76 § 15 0.36
Framingham 10-year heart risk (%) 15 (5-26) 15 (5-25) 23 (7-31) 0.37
Risk factors for SCD
History of nonsustained VT* 14 (15%) 10 (12%) 4 (40%) 0.04
Abnormal BP response* 11 (12%) 8 (9%) 3 (30%) 0.09
Symptoms
Chest pain 18 (18%) 18 (21%) - 0.20
Dyspnea (NYHA class II) 43 (44%) 40 (46%) 3 (30%) 0.51
Echocardiography
Maximal LV wall thickness (mm)* 16 (13-19) 16 (13-19) 18 (16-21) 0.08
LVMI (g/m2)* 125 (103-162) 124 (102-155) 160 (127-179) 0.05
Reduced LV systolic function* 8 (8%) 5 (6%) 3 (30%) 0.03
LV outflow tract gradient at rest 30 mm Hg 18 (19%) 18 (21%) - 0.20
Left atrial diameter (mm) 44 (39-50) 44 (39-48) 45 (42-58) 0.26
Therapy
Beta-blocker 50 (51%) 43 (49%) 7 (70%) 0.32
Calcium antagonist 12 (12%) 10 (11%) 2 (20%) 0.35
Data are presented as means § standard deviations, medians (interquartile ranges) or numbers (percentages). BP = blood pressure; LGE = late gadolinium
enhancement; LV = left ventricle; LVMI = left ventricle mass indexed to body surface area; NYHA = New York heart association; SCD = sudden cardiac
death; VT = ventricular tachycardia.
* These variables were used for multivariate logistic regression analysis.
yDyslipidemia was defined as a total cholesterol> 6.5 mmol/l.
Table 2
Biomarkers stratified according to extensive late gadolinium enhancement
Biomarkers LGE extent p value
Total <15% 15%
(n = 98) (n = 88) (n = 10)
Hs-cTnT (ng/L)* 8 (4-14) 8 (3-13) 16 (11-27) 0.001
NTproBNP (ng/L) 120 (76-351) 120 (69-323) 238 (106-360) 0.30
sST2 (ng/mL) 25 (19-34) 25 (19-35) 22 (18-31) 0.71
GDF-15 (ng/L) 837 (515-1212) 837 (510-1181) 1007 (717-1352) 0.24
Gal-3 (ng/mL) 18 (14-20) 17 (14-20) 18 (13-20) 0.79
CICP (ng/mL) 126 (106-160) 126 (106-159) 126 (104-184) 0.69
Data are presented as means § standard deviations or medians (interquartile ranges). LGE = late gadolinium enhancement.
* This variable was used for multivariate logistic regression analysis.
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history of NSVT, reduced LV systolic function and maxi-
mal echocardiographic LV wall thickness (model 1). As for
model 2, addition of hs-cTnT significantly improved the
model (difference in ¡2 log likelihood was 4.206, p = 0.04)
(Table 3). The calibration of the two models was adequate
(HosmerLemeshow goodness-of-fit significance level,
>0.05). For model 1, ROC analysis demonstrated a high
discriminative ability (area under the curve, c-statistic:
0.868 [95% confidence interval [CI] 0.780 to 0.956,
p <0.001]). For model 2, the discriminative ability was
even slightly higher (area under the curve, c-statistic: 0.900
[95% CI 0.836 to 0.964], p <0.001) (Figure 2). As a single
variable, none of the clinical characteristics (history of
NSVT, abnormal LV function, and LV wall thickness)
demonstrated valuable discriminative ability for prediction
of extensive LGE (c-statistics, p = N.S.). In contrast, ROC
analysis of hs-cTnT as a single variable demonstrated good
discriminative value (area under the curve, c-statistic of
0.818 [95% CI 0.716 to 0.920], p = 0.001) (Figure 3). Based
on the Youden index, the optimal cut-off value for hs-cTnT
was 8 ng/L. Of note, this was also the median concentration
of our cohort. Using this cutoff, the sensitivity and
specificity of hs-cTnT for extensive LGE were 100% and
54%, respectively. Consequently, the negative and positive
predictive values for extensive LGE were 100% and 19%
in our population.
Discussion
In an era of increasing interest in CMR imaging as part
of the workup to assess whether nonhigh risk HC patients
qualify for ICD implantation, we herein describe predictors
of extensive LGE. We found that a set of three clinical vari-
ables had a high discriminative value, with a significant
improvement in diagnostic accuracy after addition of hs-
cTnT. Even without accounting for the history of NSVT,
reduced LV systolic function, and maximal LV wall thick-
ness on echocardiography, a strategy based on the use of
hs-cTnT by itself showed remarkable results. Based on the
optimal cutoff for hs-cTnT, extensive LGE could reliably
be excluded in half of the cohort.
Previous reports have associated various clinical varia-
bles with the presence of LGE, such as a history of NSVT
and measures of LV hypertrophy.911 Moreover, maximal
wall thickness on CMR imaging was reported to be inde-
pendently predictive of the presence of LGE.13 As the
clinical importance of the mere presence of LGE is
Table 3
Models 1 and 2 for prediction for extensive late gadolinium enhancement
Model 1: Routine clinical variables Adjusted OR 95% CI p value
History of non-sustained VT 6.80 1.32-35.20 0.022
Maximal LV wall thickness (mm) 1.23 1.03-1.48 0.023
Reduced LV systolic function 9.31 1.48-58.40 0.017
Model 2: Routine clinical variables + biomarkers Adjusted OR 95% CI p value
History of non-sustained VT 10.00 1.54-64.78 0.016
Maximal LV wall thickness (mm) 1.23 1.012-1.497 0.037
Reduced LV systolic function 9.57 1.33-68.86 0.025
Hs-cTnT (ng/L) 1.07 1.001-1.132 .046
CI = confidence interval; LGE = late gadolinium enhancement; LV = left ventricle; OR = odds ratio; VT = ventricular tachycardia.
Figure 2. ROC curves for prediction of extensive LGE with clinical varia-
bles only (model 1) and with addition of hs-cTnT (model 2).
This figure demonstrates the discriminative ability for extensive LGE with
clinical variables only (a history of NSVT, reduced LV systolic function
and maximal LV wall thickness on echocardiography) (model 1: c-statistic:
0.868). Model 2 represents the discriminative ability with the addition of
hs-cTnT (c-statistic: 0.900).
Hs-cTnT = cardiac troponin T assessed with a highly sensitive assay; LGE
= late gadolinium enhancement.
Figure 3. ROC curve of hs-cTnT for the prediction of extensive LGE.
This figure demonstrates the discriminative ability of hs-cTnT for exten-
sive LGE in our cohort of low to intermediate risk HC patients.
Hs-cTnT = cardiac troponin T assessed with a highly sensitive assay; LGE
= late gadolinium enhancement.
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limited, we focused on the prediction of extensive LGE
and only with variables available before CMR imaging.
Our findings that a history of NSVT and a reduced LV
systolic function on echocardiography were associated
with extensive LGE corroborates with previous findings.
Clearly, myocardial scar, which is suggested by the pres-
ence of extensive LGE, is a substrate for ventricular
arrhythmias and leads to adverse remodeling.11 The asso-
ciation between maximal LV wall thickness and extensive
LGE corresponds with previous observations that HC
patients with more hypertrophy more often have LGE.9,10
This can most likely be explained by an increased myocar-
dial oxygen demand and consequent ischemia with myo-
cardial cell death.
Cardiac troponin, natriuretic peptides, and markers of
collagen turnover have been associated with the presence
of LGE in HC.1218 In addition, some studies addressed the
predictive value of these biomarkers for the presence of
LGE in HC.1214 Notably, a correlation was demonstrated
between biomarker concentrations and the extent of LGE,
although data are limited.1317,19
The other biomarkers in our panel (Gal-3, sST2, and
GDF-15) have been implicated in myocardial fibrosis,
stress, and inflammation in heart failure. Gal-3 has been
associated with LGE in nonischemic dilated cardiomyopa-
thy patients, but in HC this association could not be con-
firmed.2325 Regarding sST2 in relation to LGE CMR
imaging, only two reports in HC are available, of which
one suggested an association with LGE extent.25,26 To our
knowledge, we are the first to describe GDF-15 in relation
to LGE CMR imaging in HC.2729
With regard to our results, the observed association
between hs-cTnT and extensive LGE corroborates with pre-
vious studies and can be explained by both hs-cTnT and
LGE being markers of myocyte injury.12,13,15,18 Concerning
NTproBNP, we did not observe a difference between HC
patients with or without extensive LGE, despite a differ-
ence in systolic function among groups. Possibly, the
absence of a difference in NTproBNP may be related to the
inclusion of a nonhigh risk HC population with, in general,
low biomarker concentrations and a low incidence of exten-
sive LGE limiting the statistical power. As for concentra-
tions of CICP and the more novel markers (sST2, GDF-15,
and Galectin-3), we did not observe differences in relation
to extensive LGE. This observation may be explained by
the hypothesis that the systemic concentrations of these
markers are only partly or indirectly reflective of myocar-
dial fibrosis present in the LV myocardium.12,30 To further
assess the potential for these markers, larger studies are
warranted.24 Notwithstanding our modest sample size, our
current results put hs-cTnT forward as the most promising
biomarker for prediction of extensive LGE in nonhigh risk
HC patients.
Based on a recent meta-analysis, clinical experts have
suggested the use of extensive LGE as a SCD risk modifier
for nonhigh risk HC patients.19 The prevalence of extensive
LGE can roughly be estimated at about 10% in these
patients and implies an approximately twofold higher risk
of SCD and the consideration of ICD implantation.5,6 Nota-
bly, the majority of HC patients is at nonhigh SCD risk and
only 1 of 10 would demonstrate extensive LGE on CMR
imaging. In this context, it has recently been hypothesized
that biomarkers, and hs-cTnT in particular, may be used as
a “gateway” to perform LGE CMR imaging.7,8 A strategy
based on easily obtainable characteristics that would alter
the pretest likelihood of extensive LGE before CMR imag-
ing would increase efficacious use of LGE CMR imaging
for SCD risk stratification in HC.7,8 This may especially be
valuable for institutions with limited resources to perform
CMR imaging.
In our cohort, we demonstrated that extensive LGE can
be predicted with a high discriminatory ability with a set of
clinical variables. Importantly, the addition of hs-cTnT not
only improved prediction, but the use of hs-cTnT by itself
yielded a high discriminatory ability that approximates that
of the set of clinical variables. Obviously, prediction in
daily clinical practice based on 1 biomarker result is more
convenient than prediction based on the integration of three
different variables. To appreciate the potential of a manage-
ment strategy with hs-cTnT only, our data are put in clinical
perspective in Figure 4, demonstrating 2 important implica-
tions. First, with a 100% sensitivity at 8 ng/L, we may be
able to exclude extensive LGE in 50% of low to intermedi-
ate risk HC patients. Accordingly, in half of the patients
one might consider not to perform LGE CMR imaging for
risk stratification as no extensive LGE is expected to be
found. Second, in the other half (hs-cTnT 8 ng/L) the pre-
test probability of finding extensive LGE has increased
from 10% to 20%. As such, these data should be appreci-
ated as the first evidence that corroborates with the previ-
ously suggested hypothesis that hs-cTnT may be used as a
gateway to perform LGE CMR imaging.7,8 Importantly,
this example is intended to demonstrate potential future
implications and is not meant to be implemented in clinical
practice. Many institutions have adopted CMR imaging in
their standard initial workup for patients with suspected
HC, as CMR imaging may aid in the identification of
hypertrophy that goes unnoticed on echocardiography.
Moreover, LGE CMR imaging provides important informa-
tion that may help differentiate between sarcomeric and
nonsarcomeric causes of LV hypertrophy. Given these
unique strengths of CMR imaging, it would not be sensible
to, in general, waive CMR imaging based on a low hs-cTnT
concentration. In contrast, in case there is little doubt con-
cerning the diagnosis of HC, or in case of (relative) contra-
indications for LGE CMR imaging, hs-cTnT may provide
valuable information on the (pretest) likelihood of exten-
sive LGE.
Given the limited number of cases with LGEext and the
moderate size of our study population, our findings warrant
confirmation. Second, the definition of nonhigh SCD risk is
not uniform, due to discrepancies between the AHA/ACC
and ESC guidelines.1,2 In this context, we performed an
ancillary analysis based on the HC SCD risk-score1 and
demonstrated that hs-cTnT was independently predictive of
extensive LGE in low to intermediate risk patients accord-
ing to the ESC guidelines as well. With regard to extensive
LGE, we acknowledge that it is not (yet) included in the
guidelines, and that there is no consensus on the preferred
method of LGE quantification. Where some advocate visual
assessment, others use a signal-intensity-based cutoff, and
we chose to use a semi-quantitative score.19 In view of the
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above, caution is warranted with regard to the use of a rigid
cutoff. Our ancillary analyses with various cutoffs for
extensive LGE demonstrated that hs-cTnT remained
strongly associated with extensive LGE (Appendix B).
Consequently, these results did not materially change our
conclusions on the potential that hs-cTnT may have for
future clinical risk stratification schemes in HC.
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